hVIVO #HVO – Consultancy contract signed with Decoy Therapeutics to support development of respiratory antiviral candidates June 1, 2026 – Posted in: hVIVO (HVO)

London, UK – 1 June 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces it has signed a consultancy contract with Decoy Therapeutics (“Decoy”) to support the development of its respiratory antiviral candidates. Decoy is developing a portfolio of Designable Multi-Antiviral (D-MAV) candidates, a new antiviral category designed to address multiple viruses by targeting shared viral mechanisms across multiple respiratory viruses using a single…

hVIVO #HVO – Final Results 2025 April 15, 2026 – Posted in: Blog, hVIVO (HVO)

London, UK – 15 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces its audited results for the year ended 31 December 2025. Financial highlights · Revenue of £46.8 million (2024: £62.7 million) · Positive adjusted EBITDA of £1.4 million (2024: £16.4 million) · Adjusted EBITDA margin of 3.0% (2024: 26.2%) · Basic adjusted earnings per share of (0.41)p (2024: 1.69p) ·…

hVIVO #HVO – CEO & CFO Share Purchases December 15, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on 15 December 2025, Yamin ‘Mo’ Khan, Chief Executive Officer and Stephen Pinkerton, Chief Financial Officer, purchased shares in the Company as detailed below: Director Number of ordinary shares purchased Purchase price Resultant holding Resultant holding as a % of the issued share capital Yamin ‘Mo’ Khan 3,310,405 6.04p 8,322,008 1.21% Stephen Pinkerton 520,000 5.5p 1,270,596*…

#HVO hVIVO – POSITIVE RESULTS FROM CLIENT PHASE 2B FIELD STUDY June 30, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO recruited participants and performed the virology and immunology laboratory services for the study hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, congratulates Cidara Therapeutics (Cidara: Nasdaq CDTX) on the positive topline results from their Phase 2bfield study, for which hVIVO recruited participants and performed the virology and immunology laboratory services. The study was to determine the efficacy of Cidara’s drug-Fc conjugate, CD388, which is…

hVIVO #HVO – RSV human challenge trial contract signed with new client, Inhalon Biopharma February 3, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a contract with Inhalon Biopharma, Inc. (“Inhalon”), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections, to assess its inhaled IN-002 antiviral candidate (“IN-002”) using the hVIVO Respiratory Syncytial Virus (RSV) Human Challenge Model. The Phase 2a randomised, double-blinded…

hVIVO #HVO – Trading update – Record H1 revenue and EBITDA margin July 17, 2024 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides a trading update for the six-month period ended 30 June 2024. Highlights • Revenue of £35.6 million, 30.6% higher than H1 2023 (£27.3 million). The Board remains confident in delivering on market expectations for the full year • EBITDA margin of c.24% (H1 2023: 19.1%) •…

hVIVO #HVO – Final results April 9, 2024 – Posted in: hVIVO (HVO)

A record year across all financial and operational metrics On track to deliver future growth targets Initiating annual dividend policy hVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited results for the year ended 31 December 2023. Financial highlights • Revenue up 16% to £56.0 million (2022: £48.5 million) • EBITDA up…

Open Orphan #ORPH – CFO appointment & change of Board roles October 18, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan #ORPH (to be renamed hVIVO plc (Ticker: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Stephen Pinkerton as Chief Financial Officer (“CFO”) and as an Executive Director, effective with immediate effect. Stephen will succeed Leo Toole who steps down from the Board and CFO role to pursue other interests. Leo…

hVIVO #HVO – £13.6m RSV antiviral contract June 29, 2022 – Posted in: hVIVO (HVO)

hVIVO #HVO – £13.6m RSV antiviral contract £13.6m RSV human challenge study contract with biopharma client Study cohort sizes increase as clients recognise the benefits of human challenge hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £13.6m contract with a US-based biopharmaceutical client to…

Open Orphan #ORPH – £7.2m RSV human challenge study contract June 14, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £7.2m contract with an existing top 5 global pharmaceutical company to test its orally administered antiviral product, using hVIVO’s respiratory syncytial virus (“RSV”) Human Challenge Study Model. The Phase 2a double-blinded placebo-controlled human challenge study will take…